ADAG
Adagene IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$203.61M
P/E Ratio
—
EPS
$-0.38
Beta
0.79
52W High
$4.72
52W Low
$1.30
50-Day MA
$3.29
200-Day MA
$2.27
Dividend Yield
—
Profit Margin
-229.60%
Forward P/E
—
PEG Ratio
—
About Adagene Inc
Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.
Fundamentals
| Revenue (TTM) | $7.67M |
| Gross Profit (TTM) | $7.67M |
| EBITDA | $-21.00M |
| Operating Margin | -75.00% |
| Return on Equity | -34.40% |
| Return on Assets | -16.00% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $0.80 |
| Price-to-Book | 5.32 |
| Price-to-Sales (TTM) | 26.54 |
| EV/Revenue | 15.62 |
| EV/EBITDA | 1.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 7333.00% |
| Shares Outstanding | $47.13M |
| Float | $30.50M |
| % Insiders | 15.42% |
| % Institutions | 28.47% |
Analyst Ratings
Consensus ($9.40 target)
5
Buy1
HoldData last updated: 4/7/2026